Dupixent Lawsuit

Dupixent Lawsuit: Overview

Dupixent (dupilumab), made by Sanofi and Regeneron, is a biologic drug designed to suppress certain inflammatory pathways in the immune system, which are overactive in severe atopic dermatitis patients, asthma patients, and people with nasal polyps, eosinophilic esophagitis, and other type-2 inflammatory disorders.

While Dupixent can dramatically reduce symptoms by calming inflammation, there is growing concern that in some patients it may interfere with the immune system’s ability to detect abnormal growths of white blood cells, including skin T-cell lymphomas and other non-Hodgkin lymphoma types.

Reports suggest some patients taking Dupixent later developed cutaneous T-cell lymphoma (CTCL) or were found to have hidden lymphomas that were undiagnosed before the drug was started, often because early signs mimic eczema.

Studies indicate that with longer Dupixent use (particularly past 16 weeks) there may be an increased risk of mature T and NK cell lymphomas.

Healthcare providers and researchers are questioning whether injection site reactions or worsening skin findings in certain patients were early warnings of something more serious.

The theory is not yet conclusively proven, and many of the published cases have limitations (retrospective design, small numbers, lack of baseline biopsies), but the signal is raising alarms.

Defective drug lawyers argue that the Dupixent manufacturers failed to provide adequate warnings to patients and healthcare providers about these rare but aggressive form cancers.

In particular, when undiagnosed CTCL is present, using Dupixent may allow the disease to progress unchecked, possibly involving internal organs and more aggressive forms, including Sézary syndrome.

Important factors and developments on the links between Dupixent and CTCL

• Case reports and cohort studies have found patients with severe atopic dermatitis who started Dupixent later diagnosed with CTCL or other rare blood cancers.
• A study published in Dermatologic Therapy showed Dupixent users had a multiple-fold higher relative risk of CTCL compared to non-users.
• Clinical reviews have identified instances where Dupixent appeared to “unmask” hidden lymphomas misdiagnosed as eczema, meaning symptoms looked like dermatitis but were actually early CTCL.
• Some patients had worsening of their lymphoma once on Dupixent, especially blood involvement (e.g. Sézary syndrome) or progression of disease in internal organs after an initial skin-only presentation.
• In FAERS (FDA Adverse Event Reporting System) data and safety reports, there are hundreds of reports of lymphoma among Dupixent users, including a substantial number of CTCL cases.

Given this evidence, the core allegations in the Dupixent lawsuits are that the drug’s manufacturers Sanofi and Regeneron did not adequately warn about the possibility of CTCL, NK-cell lymphomas, and other rare cancers when prescribing Dupixent.

Plaintiffs assert that earlier detection might have prevented some of the more severe internal organ dissemination and aggressive disease in certain cases.

For defenders, much of the dispute is whether there was pre-existing, undiagnosed CTCL (hidden lymphomas), misdiagnosis, or whether Dupixent actually causes these cancers rather than simply revealing them.

Because CTCL is a rare cancer, gathering reliable epidemiologic data is challenging, but the stakes are high for anyone who suffers from these outcomes.

If you are one of the patients taking Dupixent, or a healthcare provider caring for such patients, it is important to pay attention to persistent symptoms, skin changes, or any signs not explained by typical dermatitis reactions.

CTCL Symptoms in Dupixent Users

Clinical studies have shown that some patients diagnosed with moderate to severe eczema may actually have early-stage CTCL that is mistaken for dermatitis.

In Dupixent users, the drug can sometimes worsen hidden lymphomas mistaken for skin inflammation, leading to a delayed diagnosis.

Because many patients continue treatment without recognizing the warning signs, the chance of a timely and proper diagnosis may be reduced.

Symptoms can range from mild skin symptoms to more advanced signs such as swollen lymph nodes or systemic involvement.

Reports indicate that patients with chronic sinusitis or eczema who later developed CTCL often required further testing after Dupixent use to confirm a lymphoma diagnosis.

These cases highlight the heightened risk of misidentifying rare cancers as dermatitis and the need for vigilance among healthcare providers.

Common CTCL symptoms reported in patients taking Dupixent include:

• Persistent red or scaly patches on the skin
• Itchy, dry, or painful skin lesions that do not respond to standard eczema treatments
• Enlarged or swollen lymph nodes
• Thickened or raised skin plaques
• Tumor-like growths on the skin surface
• Recurrent skin infections or slow-healing wounds

Many patients require further testing such as biopsies or blood work to distinguish CTCL from chronic dermatitis.

Without close monitoring, there is a risk of a delayed diagnosis, which can allow the disease to spread and become more aggressive.

A lymphoma diagnosis at a later stage often involves more serious complications and treatment challenges.

The overlap between eczema and CTCL makes it difficult to identify the cancer without careful medical evaluation.

For Dupixent users with unexplained or worsening scaly patches, ongoing medical review is essential to achieve a proper diagnosis and avoid missed warning signs.

What is Dupixent Used For?

Dupixent (dupilumab) is a monoclonal antibody that targets the interleukin-4 receptor alpha, blocking signaling of both IL-4 and IL-13, which are cytokines involved in many type 2 inflammatory conditions.

It has been approved by the FDA for multiple indications across skin, respiratory, and immune-mediated diseases.

Here are the current approved uses:

• Atopic Dermatitis (Eczema): For adults and children 6 months and older with moderate-to-severe atopic dermatitis not adequately controlled with topical therapies, or when topical treatments are not advisable.
• Asthma: As add-on maintenance treatment for people aged 6 years or older with moderate-to-severe asthma, especially an eosinophilic phenotype or those who are oral corticosteroid dependent.
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): For patients 12 and older whose disease is inadequately controlled.
• Eosinophilic Esophagitis (EoE): For patients aged 1 year and older.
• Prurigo Nodularis: For adult patients.
• Chronic Obstructive Pulmonary Disease (COPD): As an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
• Chronic Spontaneous Urticaria (CSU): For patients aged 12 years and older whose hives remain symptomatic despite H1 antihistamine treatment.
• Bullous Pemphigoid (BP): Recently approved (June 2025) for adult patients with bullous pemphigoid, a rare and relapsing skin blistering disease.

Dupixent cannot be used for relief of acute bronchospasm or status asthmaticus, and its use in certain indications is limited to specific patient populations (e.g. requiring the eosinophilic phenotype in asthma or COPD).

Because Dupixent is being used in more diseases, some of its latest approvals (CSU, BP, COPD) broaden the number of patients exposed, which is relevant in the litigation context.

Does the Dupixent Label Carry a Cancer Warning?

As of 2025, the official FDA prescribing information for Dupixent does not include a specific warning that the drug causes cancer.

The label discusses risks such as conjunctivitis, keratitis, eosinophilic conditions, hypersensitivity, and helminth infections, but there is no section addressing cutaneous T-cell lymphoma (CTCL) or other malignancies.

Some case reports and clinical studies have raised concerns about an association between Dupixent and rare blood cancers, especially CTCL, but these findings have not led to a formal label change.

The FDA continues to monitor adverse event data, including reports submitted to the FAERS database, as litigation and research evolve.

For now, cancer warnings remain absent from the Dupixent label, which is a major point of contention in lawsuits against the manufacturers.

Do You Qualify for the Dupixent Lawsuit?

Eligibility for the Dupixent lawsuit depends on whether a patient developed lymphoma or another serious complication after using the medication.

Attorneys review medical records and a detailed treatment history to determine if there is a connection between Dupixent use and a later cancer diagnosis.

Many claims focus on individuals who experienced worsening symptoms that were initially treated as eczema but were later found to be a rare form of cutaneous T-cell lymphoma.

TorHoerman Law offers a free case evaluation to help patients understand whether they may have a valid claim.

These lawsuits are centered on patient safety, arguing that manufacturers failed to disclose the risks and left patients vulnerable.

Those affected may be entitled to seek compensation for medical bills, lost wages, pain and suffering, and other damages.

Families of patients who developed severe or fatal complications may also qualify to pursue legal action.

Speaking with an experienced lawyer can help determine whether your circumstances meet the criteria for a Dupixent lawsuit.

Gathering Evidence for the Dupixent Lawsuit

Building a strong Dupixent lawsuit requires thorough documentation that clearly links the drug to a patient’s injuries.

Lawyers rely on detailed records that show when Dupixent was prescribed, how long it was taken, and what health changes occurred during and after treatment.

Evidence is especially important in cases where patients later developed lymphoma or other serious complications that may have been overlooked or misdiagnosed.

The more complete the documentation, the stronger the case for holding the manufacturers accountable.

Evidence that may support a Dupixent lawsuit includes:

• Complete medical records, including diagnoses and pathology reports
• A full treatment history, with dates and duration of Dupixent use
• Biopsy results showing CTCL or another lymphoma diagnosis
• Documentation of worsening symptoms or unexplained skin changes
• Records of visits with dermatologists, oncologists, or other specialists
• Pharmacy records or prescription logs confirming Dupixent prescriptions
• Imaging or laboratory results indicating spread to lymph nodes or internal organs
• Correspondence between patients and healthcare providers about ongoing concerns

Damages in Dupixent Lymphoma Lawsuit Claims

When a patient suffers harm from a prescription drug, the legal system allows them to pursue compensation for both economic and non-economic losses.

In Dupixent lymphoma cases, damages are meant to address the wide-ranging impact of a cancer diagnosis on a patient’s health, livelihood, and family life.

These claims focus on the costs of medical care, the income lost due to illness, and the personal toll of living with a rare and aggressive disease.

By seeking damages, patients and families can hold drug manufacturers accountable for the consequences of inadequate warnings and undisclosed risks.

Potential damages in a Dupixent lawsuit may include:

• Past and future medical expenses related to lymphoma treatment
• Lost wages and diminished earning capacity
• Pain and suffering caused by the disease and its treatment
• Emotional distress and reduced quality of life
• Loss of consortium or companionship for family members
• Funeral and burial expenses in wrongful death cases
• Punitive damages, if the court finds reckless conduct by the manufacturers

Potential Dupixent Lawsuit Settlement Values

At this time, there is no established settlement matrix for Dupixent lawsuits, since the litigation is still in its early stages and no MDL has been formed.

Values will potentially depend on individual factors such as medical records, treatment history, stage of cancer, and documented damages.

Because cutaneous T-cell lymphoma (CTCL) is a rare but serious condition, cases involving advanced disease, hospitalizations, or significant economic loss may be valued more highly than those with earlier intervention or limited complications.

Looking at comparable non-Hodgkin lymphoma mass torts like the Roundup lawsuit, many individual payouts have fallen in the low- to mid-six figure range (roughly $50,000 to $250,000), with severe cases potentially reaching into the seven figures in jury verdicts or high-value settlements.

These numbers are not guarantees for Dupixent claims but provide a reference point for how similar rare cancer litigation has been valued in the past.

TorHoerman Law: Investigating the Dupixent Lymphoma Lawsuit

TorHoerman Law is actively investigating claims that Dupixent may be linked to cases of cutaneous T-cell lymphoma and other rare cancers.

Our firm is committed to holding drug companies accountable when they fail to disclose risks and put patients in danger.

We know how overwhelming a cancer diagnosis can be, and we provide compassionate, knowledgeable legal support to help you pursue justice.

Every Dupixent lawsuit we handle is taken on a contingency fee basis, which means there are no upfront costs for clients.

If you or a loved one developed lymphoma after using Dupixent, you may have the right to seek compensation.

Contact us today for a free consultation or use the chat feature on this page to get in touch with our attorneys.